Observational Post-Authorisation Safety Study of Asenapine (Sycrest) (OBSERVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01734278
Recruitment Status : Active, not recruiting
First Posted : November 27, 2012
Last Update Posted : January 30, 2018
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Professor Saad Shakir, Drug Safety Research Unit, Southampton, UK

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : January 2017
  Estimated Study Completion Date : February 2018